Rituximab (Mabthera®) is a genetically engineered chimeric murine/human monoclonal antibody specific to CD20. CD20 is an approximately 35 KDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B-lymphocytes. It is absent in terminally differentiated plasma cells. The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to induce apoptosis in B cells and is used in the treatment of leukemia s and lymphomas, some autoimmune disorders, and organ transplant. EMA Bio-analytical Method Validation Guidelines and industry-recommended practices for ligand-binding assays were used for validation of this kit. BioVision’s Rituximab ELISA kit is designed to quantify/measure the Rituximab with high specificity and sensitivity in biological matrices.
产品特点
Easy, convenient, sensitive and time-saving method to measure the level of Rituximab in human serum and plasma.
Detection Range: 6.25 - 800 ng/ml
